Key Sessions
Mark Farmery
Building an Industrialised Platform for the Development and Manufacture of Next-Generation T Cell Therapies
Anocca
Cristina Martinez Munoz
Manufacturing Excellence in cell therapy
Kite Pharma EU B.V.
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Main Conference - Day 2 - GMT (Greenwich Mean Time, GMTZ)
keyboard_arrow_leftSearch & Filter
search
Streams
Clear
Main Conference - Day 2 - GMT (Greenwich Mean Time, GMTZ)
search
Streams
Clear
Showing 1 of 1 Streams
Cell Therapy Manufacturing & Analytics
11:00 - 11:05
Chairperson's Opening Remarks
- Leopold Bertea - Chief Technology Officer, Mendus AB
11:05 - 11:40
Building an Industrialised Platform for the Development and Manufacture of Next-Generation T Cell Therapies
- Mark Farmery - Chief Development Officer, Anocca
11:40 - 12:15
Large-scale manufacturing of leukemic-derived dendritic cells as a basis for novel cancer immunotherapies
- Leopold Bertea - Chief Technology Officer, Mendus AB
12:15 - 12:45
Considerations for biosafety testing of cell and gene therapies
- Richard Adair - Senior Virology Manager, SGS
Showing 1 of 1 Streams
Cell Therapy Manufacturing & Analytics
14:15 - 14:50
ProTcell: Manufacturing Challenges of T Cell Progenitor Based Therapy, A Phase III Strategy
- Pierre Heimendinger - Chief Technical Officer, Smart Immune
14:50 - 15:20
Building Flexible End-to-End Cell Therapy Manufacturing Strategies
- Luca Alberici - General Manager and Site Head, Cell and Gene Centre of Excellence, AGC Biologics
Showing 1 of 1 Streams
Cell Therapy Manufacturing & Analytics
16:00 - 16:35
Novel Analytical Technologies for Cell Therapy Product Characterisation Strategies
- Monica Raimo - Senior R&D Manager, Glycostem Therapeutics
16:35 - 17:10
Case Study: Development of Potency Assays for Cell Therapies
- Mahwish Natalia - Associate Director Cell Therapies, Takeda Oncology
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams
Clear